Cipla Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) has completed a routine current Good Manufacturing Practices (cGMP) inspection of its wholly owned subsidiary InvaGen Pharmaceuticals Inc.'s manufacturing facility in Central Islip, Long Island, New York, with a single inspectional observation.

According to the company's regulatory filing, the inspection was conducted from July 13 to July 17, 2026 (EDT) as part of the USFDA's routine cGMP inspection programme.

At the conclusion of the inspection, the USFDA issued one inspectional observation in a Form 483.

The company said it will work closely with the USFDA to comprehensively address the observation within the stipulated timeline.

A Form 483 is issued when USFDA investigators observe conditions that may constitute deviations from current Good Manufacturing Practices during an inspection. The observations are preliminary in nature and do not represent a final agency determination or regulatory action.

Cipla stated that it remains committed to resolving the observation and will continue to engage with the USFDA as part of the regulatory process.